LY2181308

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Hepatocellular CarcinomaNon-small Cell Lung Cancer

Phase 1

A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma

WithdrawnNCT00415155

Eli Lilly and CompanyHepatocellular Carcinoma

Start: 2008-08-31End: 2011-01-31Target: 60Updated: 2008-08-29

Phase 2

Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer

CompletedNCT01107444

Eli Lilly and CompanyNon-small Cell Lung Cancer

Start: 2010-05-31End: 2012-06-30Updated: 2019-09-11